uniQure (NASDAQ:QURE) Given New $14.00 Price Target at Royal Bank of Canada

uniQure (NASDAQ:QURE) had its price objective reduced by Royal Bank of Canada from $16.00 to $14.00 in a report released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on QURE. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of uniQure in a research report on Tuesday, August 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target on shares of uniQure in a research report on Wednesday. Raymond James reiterated an “outperform” rating and set a $20.00 price target on shares of uniQure in a research report on Thursday, October 10th. The Goldman Sachs Group boosted their price objective on shares of uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Finally, StockNews.com upgraded uniQure to a “sell” rating in a research note on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $17.00.

uniQure Stock Up 4.8 %

Shares of QURE opened at $7.79 on Wednesday. The company has a current ratio of 6.51, a quick ratio of 7.36 and a debt-to-equity ratio of 0.92. uniQure has a 12 month low of $3.73 and a 12 month high of $11.35. The firm’s 50 day moving average is $5.77 and its 200-day moving average is $5.83. The stock has a market capitalization of $379.71 million, a PE ratio of -1.57 and a beta of 0.90.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Equities research analysts forecast that uniQure will post -4.1 EPS for the current year.

Institutional Trading of uniQure

Hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new position in uniQure in the third quarter valued at about $53,000. Vanguard Personalized Indexing Management LLC boosted its stake in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,306 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of uniQure during the third quarter valued at about $69,000. Finally, Total Clarity Wealth Management Inc. bought a new stake in shares of uniQure during the second quarter worth about $74,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.